Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’’

A webinar in partnership with IAVI.

The Global HIV Vaccine Enterprise at the International AIDS Society and IAVI are pleased to invite you to join a webinar to discuss challenges and opportunities on the Access to future monoclonal antibodies for HIV prevention:

“Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – What would it take?’’

The Webinar features an introduction from Mark Feinberg, CEO and President of IAVI, followed by perspectives of a renowned panel of experts on R&D, manufacturing, access, policy and regulation, and a 30-minute audience Q&A.

The webinar is aimed at researchers, civil society, pharmaceutical and biotechnology companies, funders, regulators, policy makers, and other members of the global health community. The meeting will contribute to a better understanding of the huge potential of antibodies for HIV prevention, and the proposed actions to overcome the obstacles on the way to affordable global access to these tools.

Date: Monday, 23 November 2020

Time: 10:00-11:30 (EST)

Use this tool to see the time of the webinar at your location.

We look forward to you joining us!

Access to Antibodies, a Global Call to Action

As highlighted in this report published recently by IAVI and Wellcome, the potential of monoclonal antibodies (mAbs) to treat and prevent infectious and neglected diseases is enormous. Yet, with 8 mAb-based products targeting infectious diseases licensed to date, and a rapidly expanding pipeline, most of the world’s population is unlikely to have access to them, unless the global health community takes urgent action to address this inequity.

WP Twitter Auto Publish Powered By : XYZScripts.com